Gene Therapy to Target CD19 and CD22 for B-cell Acute Lymphoblastic Leukemia and Lymphoma is under clinical development by Shenzhen BinDeBio and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs for Lymphoma have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy to Target CD19 and CD22 for B-cell Acute Lymphoblastic Leukemia and Lymphoma’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gene Therapy to Target CD19 and CD22 for B-cell Acute Lymphoblastic Leukemia and Lymphoma overview

Gene therapy is under development for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia and B-cell lymphoma in children. It is administered through intrravenous route. The therapeutic candidate comprises of autologus T-cells engineered to express anti-CD19 and CD22 chimeric antigen receptor (CAR) that acts by targeting CD19 and CD22 expressing cancer cells.

For a complete picture of Gene Therapy to Target CD19 and CD22 for B-cell Acute Lymphoblastic Leukemia and Lymphoma’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 March 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.